FDA gives green signal to Luxturna for genetic blindness treatment
Date: 2017-12-20   Author: Dhananjay Punekar  Category: #news

FDA gives green signal to Luxturna for genetic blindness treatment

In a major breakthrough witnessed across the healthcare sector, the U.S. Food and Drug Administration (FDA) approved Luxturna, a kind of gene therapy to treat a rare genetic eye disease caused due to gene mutation, developed by Spark Therapeutics, a pharmaceutical startup firm. As per the FDA, the treatment has received the authorization for treating patients affected due to confirmed biallelic RPE65 mutation-related retinal dystrophy, which results in the loss of vision and can lead to complete blindness. Industry analysts have claimed that Luxturna will accrue a revenue of nearly USD 78 million next year with its sales expected to rise up to USD 238 million in 2019.

Though the key officials of Spark have not unleashed the treatment charges, experts are of the view that the therapy will cost nearly USD 1 million for the patients. After the declaration of FDA’s approval of Spark’s new gene therapy, the company’s shares rose by 4% to reach USD 50.82. According to the FDA commissioner, the approval of the new therapy is the first of its kind for treating vision loss occurring due to an inherited defect in the genes. He further stated that such new discoveries in the field of biotechnology can help in curing a plethora of dreaded diseases.

Medical experts claim that Luxturna injects a functional piece of DNA in the eye cells of the adults possessing the defective gene that causes the disease leading to blindness. According to them, the therapy is not a cure, but it is aimed at halting the growth of the disease. As per authentic sources, the ICER (Institute for Clinical and Economic Review), a U.S based nonprofit entity studying the cost-effectiveness of new procedures and therapies, plans to conduct a meeting soon to examine the effectiveness of Luxturna in January next year.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Synthetic and Bio-based Thermoplastic elastomers (TPE) Market 2023 | Synthetic and Bio-based Thermoplastic elastomers (TPE) Market
Author: Rahul Varpe

Global synthetic thermoplastic elastomers (TPE) market size was estimated at over 4 million tons in 2015 and is likely to witness gains with an estimated CAGR of more than 4.5% up to 2023. Thermoplastic elastomers market revenue is likely to be va...


Emerson expands its portfolio of valves with A.E. Valves acquisition
Author: Sunil Hebbalkar

Emerson has taken over the Verviers headquartered Advanced Engineering (A.E.) Valves, a leading manufacturer of innovative valve technology. Through this acquisition, Emerson expects to serve its consumers with a wide ...


Industrial Thermostatic Control Valves Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast to 2023
Author: Partha Ray

Global Industrial Timer Market 2018 Includes Market Size, Share, Trends, Growth, Demand, Supply, Application, Segmentation, Opportunity, Market Development, Production, Capacity Utilization, Supply, Analysis and Forecast by 2023

Electronic t...